Display options
Share it on

Curr Treat Options Allergy. 2017;4(1):43-53. doi: 10.1007/s40521-017-0117-5. Epub 2017 Mar 10.

Update on Biomarkers to Monitor Clinical Efficacy Response During and Post Treatment in Allergen Immunotherapy.

Current treatment options in allergy

Lubna Kouser, Jasper Kappen, Ross P Walton, Mohamed H Shamji

Affiliations

  1. Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Faculty of Medicine, Imperial College London, National Heart and Lung Institute, London, SW7 2AZ UK.
  2. Department of Pulmonology, STZ centre of excellence for Asthma & COPD, Sint Franciscus Vlietland group, Kleiweg 500, 3045 PM Rotterdam, The Netherlands.
  3. Airway Disease Infection Section, Imperial College London, part of the Medical Research Council and Asthma UK Centre for Allergic Mechanisms of Asthma, St. Mary's Hospital, National Heart and Lung Institute (NHLI), London, W2 1PG UK.

PMID: 28413769 PMCID: PMC5375961 DOI: 10.1007/s40521-017-0117-5

Abstract

Allergen immunotherapy (AIT) is an immune modulating treatment for allergic diseases. Although highly effective, some patients do not respond to the treatment. To date there are no surrogate biomarkers that are predictive of the clinical response to AIT. More and more is known about the underlying immunological mechanism involved in AIT. Through modulation of both innate and adaptive immune responses, involving reduced ILC2 and enhanced Treg and Breg induction and functionality, along with induction of IgG4 antibody production which have the capacity to inhibit both allergen-induced basophil responsiveness and CD23-mediated IgE-facilitated allergen presentation, the result is an immune skewing towards a more balanced Type I response. So far, however there is not a clear correlation with the observed immunological changes and predictive correlates of clinical efficacy. The most promising biomarker of successful AIT is IgE-FAB as a reflection of functional IgG4. Cellular responses and cytokine analysis gives a great deal of insight into the mechanisms of AIT but may not represent useful or indeed reliable biomarkers in a clinical setting. There is a need for more research for confirmation and interpretation of the possible association with biomarkers and clinical response to AIT.

Keywords: AIT; Allergen immunotherapy; Biomarkers; ILC2; IgG4; Tregs

References

  1. Immunol Allergy Clin North Am. 2006 May;26(2):307-19, viii - PubMed
  2. J Clin Invest. 1987 Apr;79(4):1197-203 - PubMed
  3. Ann Allergy Asthma Immunol. 1998 Nov;81(5):401-5 - PubMed
  4. J Immunol. 2013 Dec 1;191(11):5349-53 - PubMed
  5. Annu Rev Immunol. 2012;30:647-75 - PubMed
  6. Allergy. 2002 May;57(5):423-30 - PubMed
  7. J Exp Med. 2013 Dec 16;210(13):2939-50 - PubMed
  8. J Allergy Clin Immunol. 2005 Sep;116(3):608-13 - PubMed
  9. Clin Exp Allergy. 2015 Oct;45(10):1542-53 - PubMed
  10. J Allergy Clin Immunol. 2011 Feb;127(2):509-516.e1-5 - PubMed
  11. J Allergy Clin Immunol. 2013 Apr;131(4):1204-12 - PubMed
  12. Int Arch Allergy Immunol. 2006;141(2):119-29 - PubMed
  13. Curr Opin Pulm Med. 2014 Jan;20(1):109-17 - PubMed
  14. J Allergy Clin Immunol. 2014 Apr;133(4):1203-5 - PubMed
  15. Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13921-6 - PubMed
  16. J Allergy Clin Immunol. 2005 Aug;116(2):347-54 - PubMed
  17. Allergy. 2007 Nov;62(11):1335-8 - PubMed
  18. Clin Exp Allergy. 2010 Sep;40(9):1365-77 - PubMed
  19. J Allergy Clin Immunol. 2012 Nov;130(5):1049-62 - PubMed
  20. Auris Nasus Larynx. 1987;14(2):77-86 - PubMed
  21. World Allergy Organ J. 2015 May 14;8(1):17 - PubMed
  22. J Allergy Clin Immunol. 2011 Jan;127(1):72-80, 80.e1-2 - PubMed
  23. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-334 - PubMed
  24. Int Arch Allergy Immunol. 2004 Apr;133(4):317-29 - PubMed
  25. Clin Exp Allergy. 2014 Mar;44(3):417-28 - PubMed
  26. Clin Exp Allergy. 2011 Sep;41(9):1235-46 - PubMed
  27. N Engl J Med. 1999 Aug 12;341(7):468-75 - PubMed
  28. Annu Rev Immunol. 2012;30:221-41 - PubMed
  29. Int Arch Allergy Immunol. 2003 Sep;132(1):68-75 - PubMed
  30. J Allergy Clin Immunol. 1991 Sep;88(3 Pt 1):328-38 - PubMed
  31. J Allergy Clin Immunol. 2015 Apr;135(4):913-21.e9 - PubMed
  32. Allergy. 1995 Jun;50(6):463-72 - PubMed
  33. Allergol Int. 2013 Dec;62(4):403-13 - PubMed
  34. Cochrane Database Syst Rev. 2010 Dec 08;(12):CD002893 - PubMed
  35. Nature. 2015 Jan 15;517(7534):293-301 - PubMed
  36. Clin Exp Allergy. 2010 Jun;40(6):922-32 - PubMed
  37. Ther Adv Respir Dis. 2017 Jan;11(1):73-86 - PubMed
  38. Allergy. 2016 Apr;71(4):475-94 - PubMed
  39. J Immunol. 2004 Mar 1;172(5):3252-9 - PubMed
  40. J Allergy Clin Immunol. 2012 Feb;129(2):544-51, 551.e1-7 - PubMed
  41. Cell. 2008 May 30;133(5):775-87 - PubMed
  42. Allergy. 2008 Apr;63 Suppl 86:8-160 - PubMed
  43. Allergy. 2012 Feb;67(2):217-26 - PubMed
  44. J Allergy Clin Immunol. 2012 Apr;129(4):1020-30 - PubMed
  45. Clin Exp Allergy. 1999 Apr;29(4):497-506 - PubMed
  46. Cochrane Database Syst Rev. 2011 Jul 06;(7):CD007685 - PubMed
  47. J Allergy Clin Immunol. 2016 May;137(5):1289-300 - PubMed
  48. J Allergy Clin Immunol. 2016 Feb;137(2):545-58 - PubMed
  49. Sci Transl Med. 2013 Jan 30;5(170):170ra16 - PubMed
  50. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001936 - PubMed
  51. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62 - PubMed
  52. J Allergy Clin Immunol. 2014 Nov;134(5):1193-5.e4 - PubMed
  53. J Allergy Clin Immunol. 2014 Jan;133(1):130-8.e1-2 - PubMed
  54. J Allergy Clin Immunol. 2000 Oct;106(4):677-86 - PubMed
  55. Libyan J Med. 2010 Jun 21;5:null - PubMed
  56. J Immunol. 1972 Apr;108(4):1000-8 - PubMed
  57. Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):586-93 - PubMed
  58. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55 - PubMed
  59. J Allergy Clin Immunol. 2008 Jun;121(6):1467-72, 1472.e1 - PubMed
  60. J Allergy Clin Immunol. 2016 Jul;138(1):305-8 - PubMed
  61. Expert Rev Clin Immunol. 2016 Nov;12 (11):1141-1151 - PubMed

Publication Types

Grant support